期刊文献+

达格列净联合二甲双胍治疗2型糖尿病的临床观察 被引量:6

Clinical observation of dapagliflozin combined with metformin in treatment of type 2 diabetes mellius
下载PDF
导出
摘要 目的探讨达格列净联合二甲双胍治疗2型糖尿病的临床效果。方法60例服用二甲双胍治疗血糖控制不佳的2型糖尿病患者,随机分为对照组和观察组,每组30例。对照组患者使用二甲双胍联合格列美脲治疗,观察组患者使用二甲双胍联合达格列净治疗。比较两组患者治疗前后空腹血糖(FBG)、餐后2 h血糖(2 h PBG)、糖化血红蛋白(HbA1c)、体质量指数(BMI)及不良反应发生情况。结果治疗12周后,两组患者FBG、2 h PBG、HbA1c均低于本组治疗前,差异有统计学意义(P<0.05);两组FBG、2 h PBG、HbA1c比较差异无统计学意义(P>0.05);观察组患者BMI较本组治疗前明显下降,差异具有统计学意义(P<0.05);对照组患者BMI与治疗前比较差异无统计学意义(P>0.05);观察组患者BMI(22.4±1.4)kg/m2低于对照组的(24.7±1.8)kg/m2,差异具有统计学意义(P<0.05)。观察组低血糖发生率为3.33%,明显低于对照组的20.00%,差异有统计学意义(P<0.05)。观察组总不良反应发生率为20.00%,低于对照组的26.67%,但差异无统计学意义(P>0.05)。结论口服二甲双胍联合达格列净对于2型糖尿病患者的降糖效果肯定,有利于体重的控制,且不良反应少,使用方便,值得推广。 Objective To discuss the clinical effect of dapagliflozin combined with metformin in treatment of type 2 diabetes mellius.Methods A total of 60 type 2 diabetes mellius patients with poor glucose control treated by metformin were randomly divided into control group and observation group,with 30 cases in each group.The control group was treated with metformin and glimepiride,and the observation group was treated with metformin and dapagliflozin.Comparison was made on fasting blood glucose,postprandial 2 h blood glucose(2 h PBG),glycosylated hemoglobin(HbA1c),body mass index(BMI)before and after treatment and occurrence of adverse reactions between the two groups.Results After 12 weeks of treatment,the levels of FBG,2 h PBG and HbA1c in the two groups was obviously lower than those before treatment,and the difference was statistically significant(P<0.05).There was no statistically significant difference in FBG,2 h PBG and HbA1c between the two groups(P>0.05).The BMI in the observation group was obviously decreased than that before treatment,and the difference was statistically significant(P<0.05).There was no statistically significant difference in BMI in the control group before and after treatment(P>0.05).The BMI(22.4±1.4)kg/m2 in the observation group was lower than(24.7±1.8)kg/m2 in the control group,and the difference was statistically significant(P<0.05).The incidence of hypoglycemia was 3.33%in the observation group,which was obviously lower than 20.00%in the control group,and the difference was statistically significant(P<0.05).The incidence of total adverse reactions was 20.00%in the observation group,which was lower than 26.67%in the control group,but the difference was not statistically significant(P>0.05).Conclusion Oral metformin combined with dapagliflozin has definite hypoglycemic effect on type 2 diabetes mellitus,which is beneficial to weight control and easy to use with less adverse reactions.It is worth promoting.
作者 黄霞 HUANG Xia(Department of Endocrinology,Taizhou Second People’s Hospital,Taizhou 225500,China)
出处 《中国实用医药》 2019年第32期8-10,共3页 China Practical Medicine
关键词 2型糖尿病 达格列净 二甲双胍 格列美脲 Type 2 diabetes mellius Dapagliflozin Metformin Glimepiride
  • 相关文献

参考文献10

二级参考文献60

  • 1中华医学会糖尿病学分会.中国2型糖尿病防治指南(2010年版)[J].中华糖尿病杂志,2010,2增刊2:1-56.
  • 2Yanai H, Adachi I-I, Hamasaki H, et al. Effects of 6-month sitagliptin treatment on glucose and lipid metabolism, blood pressure, body weight and renal function in type 2 diabetic patients: a chart-based analysis [ J]. J Clin Med Res, 2012,4: 251-258.
  • 3Mohan V, Yang WY, Son HY, et al. Efficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China, India, and Korea[J]. Diabetes Res Clin Pract,2009,83: 106-116.
  • 4Aschner P, Katzeff HL, Guo H, et al. Efficacy and safety of monotherapy of sitagliptin compared with metformin in patients with type 2 diabetes [ J ]. Diabetes Obes Metab,2010,12:252-261.
  • 5Liu Y, Hong T. Combination therapy of dipeptidyl peptidase-4 inhibitors and metformin in type 2 diabetes: rationale and evidence. Diabetes Obes Metab, 2013 [ 2013-06-02 ] . http:/! dx. doi. org/10, 1111/dom. 12128. [ published online ahead of print May 13,2013 ].
  • 6Williams-Herman D, Johnson J,Teng R, et al. Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotberapy over 2 years in patients with type 2 diabetes [ J ]. Diabetes Obes Metab,2010, 12: 442-451.
  • 7Sakamoto Y, Oyama J, Ikeda H, et al. Effects of sitagliptin beyond glycemic control: focus on quality of life[ J]. Cardiovasc Diabetol, 2013,12:35.
  • 8Shah Z, Pineda Z, Kampfrath T, et al. Acute DPP4 inhibition modulates vascular tone through GLP-1 independent pathways[ J]. Vascul Pharmaco1,2011,55 :2-9.
  • 9Yu Xu,Limin Wang,Jiang He,et al.For the 2010 China Noncommunicable Disease Surveillance Group.Prevalence and Control of Diabetes in Chinese[J].JAMA,2013,310(9):948-959.
  • 10Lee YJ,Lee YJ,Han HJ.Regulatory mechanisms of Na(+)/glucose cotransporters in renal proximal tubule cells[J].Kidney Int Suppl 2007,(106):S27-35.

共引文献5448

同被引文献73

二级引证文献39

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部